Artesunate + amodiaquine (WHO prequalified Artesunate/Amodiaquine Winthrop®) was administered orally as a fixed dose combination, at a dose of approximately artesunate 4 mg/kg + amodiaquine 10mg/kg once daily for 3 consecutive days. Primaquine was administered orally, as a single dose (0.25 mg/kg) together with the first artesunate + amodiaquine dose. All doses of medicine were administered under direct supervision. Any patient who vomited within a 30 minute observation period was re-treated with the same dose of medicine and observed for an additional 30 minutes. If the patient vomited again after the second study drug administration, he/she was withdrawn and offered rescue therapy (Artesunate IV).

Plasmodium Falciparum Malaria

Three day treatment with ASAQ with SLD primaquine given with the first dose of ASAQ.

Artesunate-amodiaquine given with single low dose primaquine

Micheweni, Bububu Jesheni, and Uzini

Efficacy and Safety of Artesunate + Amodiaquine With SLD of Primaquine for Treatment of Falciparum Malaria in Zanzibar

Efficacy and Safety of Artesunate + Amodiaquine Combined With a Single Low Dose of Primaquine (0.25 mg/kg) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Zanzibar

PCR corrected cure rates were to be assessed by genotype analysis of the following P. falciparum genes: the merozoite surface protein 1 (msp1) and 2 (msp2), and the glutamine-rich protein (glurp) (WHO 2008). The genotypic profiles of pre- and post-parasite strains were to be compared in a stepwise manner to distinguish recrudescence from reinfection.

Incidence of adverse events, particularly with regards to potential hematological adverse events of primaquine.

Prevalence of genetic polymorphisms associated with artesunate + amodiaquine tolerance/resistance. I.e., prevalence of genetic markers in the P. falciparum chloroquine resistance transporter gene (pfcrt), the multidrug resistance gene 1 (pfmdr1), and in the Kelch 13 propeller region.

Professor Anders Björkman

Professor

Ministry of Health and Social Welfare, Zanzibar

Zanzibar Malaria Elimination Programme

Uppsala University

A one-armed prospective antimalarial drug efficacy trial.

40 patients will be instructed to consume 600 ml of the special "immune-enhancing" formula plus 20 g glutamine (Supportan R + Glutamine plus R, which contain 900 Kcal and 60 g protein/day, with 24.4 g glutamine, 2,2 g arginine and 4.4 g of omega 3 fatty acids, in a lower volume due to its higher energy density).

40 patients that do not agree to participate, do not have enough time before the operation, do not tolerate the product and/or drink less than 100 cc/day.

CANCER

600 ML OF AN ENERGY DENSE DRINK PLUS 20 G GLUTAMINE POWDER (to give 900 Kcal and 80 g protein/day)

SUPPORTAN + GLUTAMINE PLUS

Patients will be assessed and followed, but will receive no special nutritional support before the surgical procedure

NO PREOPERATIVE NUTRITION SUPPORT

site of publication of A.S.P.E.N. guidelines

Oncologic Hospital Fundacion Arturo Lopez Perez

Clinical Benefits of Preoperative Nutrition Support With Enteral Immune-enhancing Formulas in Surgical Oncology

Preoperative Nutrition Support in Major Oncologic Surgery

Registration of all eventual surgical complication after oncologic surgery, both during hospital stay and after 30 days after hospital discharge

MARIA PIA DE LA MAZA

University of Chile

peripheral blood leukocyte DNA and plasma

glutamine/ateş

Efficacy and Safety of Artesunate + Amodiaquine With SLD of Primaquine for Treatment of Falciparum Malaria in Zanzibar

Clinical Benefits of Preoperative Nutrition Support With Enteral Immune-enhancing Formulas in Surgical Oncology

Toll-like Receptor 2 Gene Polymorphism, Serum Cytokines and Susceptibility to Disease Severity or Treatment Response of Pulmonary Tuberculosis

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı